Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Tessa Gargett"'
Autor:
Gonzalo Tapia Rico, Michael P Brown, Andrew Ruszkiewicz, Amy Johnson, Tessa Gargett, Nga T H Truong, Wenbo Yu, Erica C F Yeo, Nicole L Wittwer, Bryan Gardam, Jesikah Logan, Purany Sivaloganathan, Maria Collis
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 5 (2024)
Background Chimeric antigen receptor (CAR) T cell therapies specific for the CD19 and B-cell maturation antigen have become an approved standard of care worldwide for relapsed and refractory B-cell malignancies. If CAR-T cell therapy for non-hematolo
Externí odkaz:
https://doaj.org/article/8e9e3a75af7840e99fd72a527e82ccbb
Autor:
Wenbo Yu, Nga TH Truong, Ruhi Polara, Tessa Gargett, Melinda N Tea, Stuart M Pitson, Michaelia P Cockshell, Claudine S Bonder, Lisa M Ebert, Michael P Brown
Publikováno v:
Clinical & Translational Immunology, Vol 13, Iss 7, Pp n/a-n/a (2024)
Abstract Objectives CAR‐T cells are being investigated as a novel immunotherapy for glioblastoma, but clinical success has been limited. We recently described fibroblast activation protein (FAP) as an ideal target antigen for glioblastoma immunothe
Externí odkaz:
https://doaj.org/article/015396e342d8443aa4091f21f509b391
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Glioblastoma is an aggressive primary brain tumor that has seen few advances in treatments for over 20 years. In response to this desperate clinical need, multiple immunotherapy strategies are under development, including CAR-T cells, immune checkpoi
Externí odkaz:
https://doaj.org/article/6762158048054266956a8a5542d01d3c
Autor:
Jake Nowicki, Michael P Brown, Tessa Gargett, Lisa M Ebert, Nga T H Truong, Paris M Kollis, Kristyna Sedivakova, Wenbo Yu, Erica C F Yeo, Nicole L Wittwer, Briony L Gliddon, Melinda N Tea, Rebecca Ormsby, Santosh Poonnoose, Orazio Vittorio, David S Ziegler, Stuart M Pitson
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 9 (2022)
Background Aggressive primary brain tumors such as glioblastoma are uniquely challenging to treat. The intracranial location poses barriers to therapy, and the potential for severe toxicity. Effective treatments for primary brain tumors are limited,
Externí odkaz:
https://doaj.org/article/aeb6b5a8c73041bf87654aafeab489d5
Autor:
Paris M. Kollis, Lisa M. Ebert, John Toubia, Cameron R. Bastow, Rebecca J. Ormsby, Santosh I. Poonnoose, Sakthi Lenin, Melinda N. Tea, Stuart M. Pitson, Guillermo A. Gomez, Michael P. Brown, Tessa Gargett
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Glioblastoma is the most common and aggressive form of primary brain cancer, with no improvements in the 5-year survival rate of 4.6% over the past three decades. T-cell-based immunotherapies such as immune-checkpoint inhibitors and chimeric antigen
Externí odkaz:
https://doaj.org/article/acdaa2cfb7ca4c1c9e49370d3b46e739
Publikováno v:
Clinical & Translational Immunology, Vol 10, Iss 8, Pp n/a-n/a (2021)
Externí odkaz:
https://doaj.org/article/4dc1466151fc4ec189c0cad68eadb6df
Autor:
Lisa M Ebert, Wenbo Yu, Tessa Gargett, John Toubia, Paris M Kollis, Melinda N Tea, Brenton W Ebert, Cedric Bardy, Mark van den Hurk, Claudine S Bonder, Jim Manavis, Kathleen S Ensbey, Mariana Oksdath Mansilla, Kaitlin G Scheer, Sally L Perrin, Rebecca J Ormsby, Santosh Poonnoose, Barbara Koszyca, Stuart M Pitson, Bryan W Day, Guillermo A Gomez, Michael P Brown
Publikováno v:
Clinical & Translational Immunology, Vol 9, Iss 10, Pp n/a-n/a (2020)
Abstract Objectives Targeted immunotherapies such as chimeric antigen receptor (CAR)‐T cells are emerging as attractive treatment options for glioblastoma, but rely on identification of a suitable tumor antigen. We validated a new target antigen fo
Externí odkaz:
https://doaj.org/article/d95e2e808e74470a9794a5b6b9f9e770
Publikováno v:
Clinical & Translational Immunology, Vol 8, Iss 5, Pp n/a-n/a (2019)
Abstract Chimeric antigen receptor (CAR)‐T cell therapy is now approved in the United States and Europe as a standard treatment for relapsed/refractory B‐cell malignancies. It has also been approved recently by the Therapeutic Goods Administratio
Externí odkaz:
https://doaj.org/article/ce6860ad64564d9195df799e2e26563c
Publikováno v:
Cells, Vol 10, Iss 3, p 607 (2021)
Glioblastoma is the most common form of primary brain tumour in adults. For more than a decade, conventional treatment has produced a relatively modest improvement in the overall survival of glioblastoma patients. The immunosuppressive mechanisms emp
Externí odkaz:
https://doaj.org/article/fc6c663dc6934ee0be996a62d1eb2886
Autor:
Siok-Keen Tey, Geoffrey R. Hill, Cameron I. Curley, A. James Morton, Glen A. Kennedy, Gary R. Pratt, Cheryl Hutchins, Devika Ganesamoorthy, Lachlan J. Coin, Michael P. Brown, Tessa Gargett, Judy Avery, Nienke Zomerdijk, Elise Sturgeon, Luke D. Samson, Stuart D. Olver, Kate H. Gartlan, Antiopi Varelias, Raymond Au, Md Ashik Ullah, Jyothy Raju, Ping Zhang
Supplemental Material
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61dce7f3501497710be1558e6ff443ae
https://doi.org/10.1158/1078-0432.22474131.v1
https://doi.org/10.1158/1078-0432.22474131.v1
